A biomarker-guided predictive care company, Bodyport, showed that its FDA-cleared, non-invasive technology for remote heart failure monitoring detected twice as many heart failure events when compared to current standard of care. Data were presented at the third annual Technology and Heart Failure Therapeutics conference in Boston. During the study, the congestion index correctly predicted 48 of 69 heart failure events (70%), demonstrating higher sensitivity (p<0.01) than the weight-scale standard of care.

Reference: Diagnostic and Interventional Cardiology. Accessed June 10, 2024. https://www.dicardiology.com/content/bodyport-presents-preliminary-analysis-scale-hf-1-study-remote-heart-failure-monitoring